The White House psychedelics executive order accelerates research, clinical trials and “Right to Try” access for drugs like psilocybin, MDMA and ibogaine.

A White House executive order on psychedelics, signed by President Donald Trump on Saturday, aims to speed up research on drugs like psilocybin, MDMA and ibogaine, helping to legitimize an industry t…